The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells

Nature Medicine

Volumn 2, Issue 12, 1996, Pages 1371-1375

  Albini, Adriana ^b   Soldi, Raffaella ^a   Giunciuglio, Daniela ^b   Giraudo, Enrico ^a   Benelli, Roberto ^b   Primo, Luca ^a   Noonan, Douglas ^b   Salio, Mariolina ^a   Camussi, Giovanni ^c   Rockl, Wolfang ^d   Bussolino, Federico ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; RECEPTOR; TRANSACTIVATOR PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BINDING SITES; CHEMOTAXIS; COLLAGEN; COS CELLS; DRUG COMBINATIONS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GENE PRODUCTS, TAT; HIV-1; HUMANS; LAMININ; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEOGLYCANS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS MUSCULUS;

EID: 16144363412     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1296-1371     Document Type: Article

References (23)

1. Vaishnaw, Y.N. & Wong-Staal, F. The biochemistry of AIDS. Annu. Rev. Biochem. 60, 577-630 (1991).
2. Ensoli, B. et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J. Virol. 67, 277-287 (1993).
3. Westendorp, M.O. et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375, 497-500 (1995).
4. Lotz, M., Clark-Lewis, I. & Ganu, V. HIV-transactivator Tat induces proliferation and TGF beta expression in human articular chondrocytes. J. Cell Biol. 1245, 365-371 (1994).
5. Barillari, G. et al. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression: Implications for AIDS-Kaposi's sarcoma pathogenesis. J. Immunol. 149, 3727-3734 (1992).
6. Hofman, F.M., Dohadwala, M.M., Wright, A.D., Hinton, D.R. & Walker, S.M. Exogenous Tat protein activates central nervous system-derived endothelial cells. J. Neuroimmunol. 54, 19-28 (1994).
7. Albini, A. et al. HIV-Tat protein is a heparin-binding angiogenic growth factor. Oncogene 12, 289-297 (1996).
8. Ensoli, B., Barillari, G., Salahuddin, S.Z., Gallo, R.C. & Wong-Staal, F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345, 84-86 (1990).
9. Ensoli, B. et al. In vitro and in vivo evidence that basic fibroblast growth factor and human immunodeficiency virus type-1 Tat protein synergize in inducing Kaposi's sarcoma development. Nature 371, 674-680 (1994).
10. Vogel, J., Hinrichs, S.H., Reynolds, R.K., Luciw, P.A. & Jay, G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 335, 606-611 (1988).
11. Corallini, A. et al. Promotion of tumor metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS 10, 701-710 (1996).
12. Corallini, A. et al. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res. 53, 5569-5575 (1993)
13. Thomas, K.A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271, 603-606 (1996).
14. Albini, A. et al. Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 Tat product: Inhibition of KS-like lesions by tissues inhibitor of metalloproteinase-2. AIDS 8, 1237-1244 (1994).
15. Mandriota, S.J. et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J. Biol. Chem. 270, 9709-9716 (1995).
16. Friedlander, M. et al. Definition of two angiogenic pathways by distinct α integrins. Science 270, 1500-1502 (1995).
17. Vaisman, N., Gospodarowicz, D. & Neufeld, G. Characterization of the receptors for vascular endothelial growth factor. J. Biol. Chem. 265, 19461-19466 (1990).
18. Barnett, S.W., Murthy, K.K., Herndier, B.G. & Levy, J.A. An AIDS-like condition induced in baboons by HIV-2. Science 266, 642-646 (1994).
19. Moore, P. & Chang, Y. Detection of herpesvirus-like sequences in Kaposi's sarcoma in patients with and those without HIV infection. N. Engl. J. Med. 332, 1181-1185 (1995).
20. Safai, B. et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Annu. Intern. Med. 103, 744-750 (1985).
21. Robbins, K.C., Antoniades, H.N., Devare, S.G., Hunkapiller, M.W. & Aaronson, S.A. Structural and immunological similarities between simian virus gene product(s) and human platelet-derived growth factor. Nature 305, 605-608 (1983).
22. Kaner, R.J. et al. Fibroblast growth factor receptor is a portal of cellular entry for herpes simplex virus type I. Science 248, 1410-1413 (1990).
23. Bussolino, F. et al. Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis. J. Clin. Invest. 96, 940-952 (1995).